XRAY:NGS-DENTSPLY SIRONA Inc. (USD)

EQUITY | Medical Instruments & Supplies | Nasdaq Global Select

Last Closing

USD 30.57

Change

0.00 (0.00)%

Market Cap

USD 13.82B

Volume

1.16M

Analyst Target

USD 48.77
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Dentsply Sirona Inc is a designer, developer, manufacturer and marketer of consumable dental products for the professional dental market. The Company also manufactures and markets other consumable medical device products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

-5.82 (-1.51%)

USD 133.13B
COO The Cooper Companies Inc.

-1.93 (-2.04%)

USD 18.82B
HOLX Hologic Inc

+0.43 (+0.57%)

USD 17.83B
RGEN Repligen Corporation

-3.47 (-2.08%)

USD 9.30B
MMSI Merit Medical Systems Inc

N/A

USD 4.28B
AZTA Azenta Inc

-0.26 (-0.50%)

USD 2.78B
ICUI ICU Medical Inc

+1.27 (+1.19%)

USD 2.31B
STAA STAAR Surgical Company

+1.22 (+2.88%)

USD 2.31B
LMAT LeMaitre Vascular Inc

+0.08 (+0.11%)

USD 1.47B
ATRC AtriCure Inc

+0.17 (+0.76%)

USD 1.08B

ETFs Containing XRAY

HBD:CA BetaPro Gold Bullion 2x D.. 6.53 % 1.52 %

+0.24 (+0%)

CAD 1.80M
HND:CA BetaPro Natural Gas 2x Da.. 6.04 % 1.52 %

-5.90 (0%)

CAD 0.06B
MVUS:SW 3.32 % 0.00 %

N/A

N/A
SPMV:SW 3.32 % 0.00 %

N/A

N/A
RNMC First Trust Mid Cap US Eq.. 0.00 % 0.60 %

+0.02 (+0%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.11% 47% F 32% F
Dividend Return 0.45% 60% D- 28% F
Total Return -13.66% 47% F 32% F
Trailing 12 Months  
Capital Gain -27.09% 50% F 30% F
Dividend Return 1.38% 83% B 19% F
Total Return -25.71% 50% F 30% F
Trailing 5 Years  
Capital Gain -39.57% 46% F 32% F
Dividend Return 4.59% 60% D- 16% F
Total Return -34.98% 46% F 32% F
Average Annual (5 Year Horizon)  
Capital Gain -5.03% 43% F 33% F
Dividend Return -4.04% 43% F 33% F
Total Return 0.99% 50% F 25% F
Risk Return Profile  
Volatility (Standard Deviation) 30.03% 73% C 61% D-
Risk Adjusted Return -13.46% 43% F 34% F
Market Capitalization 13.82B 90% A- 90% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 30.90 68% 41%
Price/Book Ratio 1.97 63% 48%
Price / Cash Flow Ratio 16.84 34% 16%
Price/Free Cash Flow Ratio 33.99 15% 7%
Management Effectiveness  
Return on Equity -3.72% 63% 55%
Return on Invested Capital 6.05% 78% 71%
Return on Assets 2.41% 70% 76%
Debt to Equity Ratio 54.54% 22% 40%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.